Daniel Chelliah, MD
Infectious Disease · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: 757662 · El Camino Health. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chelliah’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A121423 · Current
Licensed to practise in California · since 2012 · expires 2028-02-29 · Loma Linda University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$83,575
Medicare paid this office $83,575 for 213 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $41,542 | $106 |
| Long return visit (40+ min) | 66 | $16,479 | $165 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 66 | $10,823 | $155 |
| New patient visit (60+ min) | 24 | $4,453 | $186 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 38 | $2,239 | $44 |
See all 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $41,542 | $106 |
| Long return visit (40+ min) | 66 | $16,479 | $165 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 66 | $10,823 | $155 |
| New patient visit (60+ min) | 24 | $4,453 | $186 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 38 | $2,239 | $44 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,203 | $71 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 13 | $225 | $15 |
Who their Medicare patients are
213 Original Medicare patients in 2024. Average age 77 · Under 65 10% · 85 and older 23% · Women 47% · Also on Medicaid 26% · Health risk score 2.57. At or below the middle of the specialty; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Diabetes 43% · Chronic kidney disease 43% · Atrial fibrillation 40% · Coronary heart disease 39% · Heart failure 35% · Depression 35% · COPD 33% · Dementia 28% · Cancer 26% · Stroke 17%.
The office billed $299,905, Medicare allowed $106,531 and paid $83,575; for 721 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 213 | 721 | 77 | 2.57 | $299,905 | $83,575 |
| 2023 | 191 | 651 | 77 | 2.35 | $272,966 | $81,137 |
| 2022 | 227 | 872 | 75 | 2.78 | $327,459 | $92,317 |
| 2021 | 246 | 788 | 76 | 2.49 | $313,748 | $95,544 |
| 2020 | 209 | 715 | 75 | 2.86 | $233,138 | $78,426 |
| 2019 | 262 | 1,190 | 76 | 2.78 | $324,183 | $97,691 |
| 2018 | 248 | 1,041 | 76 | 2.87 | $281,908 | $87,157 |
| 2017 | 217 | 769 | 75 | 2.72 | $254,432 | $79,922 |
| 2016 | 70 | 185 | 75 | 2.38 | $54,022 | $17,194 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 118 | $37,300 | $111 |
| Long return visit (40+ min) | 66 | $20,743 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $10,673 | $155 |
| New patient visit (60+ min) | 23 | $4,509 | $196 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 28 | $2,077 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,744 | $73 |
2022: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 158 | $47,694 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $17,039 | $181 |
| Long return visit (40+ min) | 55 | $15,635 | $165 |
| New patient visit (60+ min) | 26 | $5,326 | $205 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,928 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,409 | $74 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $873 | $35 |
2021: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 158 | $37,533 | $97 |
| Long return visit (40+ min) | 60 | $20,908 | $173 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $19,880 | $184 |
| New patient visit (60+ min) | 34 | $7,281 | $214 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,969 | $78 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 29 | $1,390 | $38 |
2020: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 123 | $39,723 | $102 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $16,979 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $7,076 | $81 |
| Long return visit (40+ min) | 24 | $4,586 | $143 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $2,408 | $109 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 34 | $1,933 | $40 |
| Return visit (30+ min) | 12 | $1,317 | $110 |
2019: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 183 | $55,548 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $18,425 | $184 |
| Long return visit (40+ min) | 77 | $15,179 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $1,945 | $61 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 36 | $1,355 | $35 |
| Return visit (30+ min) | 11 | $1,153 | $105 |
2018: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 153 | $44,061 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 82 | $16,009 | $182 |
| Long return visit (40+ min) | 71 | $15,927 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $2,811 | $64 |
| Return visit (30+ min) | 16 | $1,721 | $101 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 24 | $979 | $35 |
2017: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 125 | $38,344 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $15,591 | $181 |
| Long return visit (40+ min) | 65 | $12,485 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $4,599 | $65 |
| Return visit (30+ min) | 28 | $3,546 | $101 |
| New patient visit (60+ min) | 14 | $2,663 | $190 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $419 | $35 |
2016: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $5,926 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,922 | $64 |
| Long return visit (40+ min) | 17 | $3,096 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,163 | $180 |
Medicaid work
$1,070 in 2024
Medicaid paid $1,070 for 53 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 53 | $1,070 |
| 2024 | 53 | 1 | 13 | $1,070 |
| 2023 | 20 | 1 | 12 | $2,583 |
| 2022 | 65 | 1 | 12 | $3,625 |
| 2019 | 30 | 1 | 12 | $781 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 20 | $2,583 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 65 | $3,625 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 30 | $781 |
Drugs they prescribed that Part D paid
$471,882
Pharmacies billed $471,882 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 396) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
300 generic and 96 brand-name prescriptions · $471,882 in drug cost · 192 antibiotic prescriptions to 52 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Genvoya | 28 | $140,305 | $5,011 |
| Biktarvy | 25 | $106,819 | $4,273 |
| Odefsey | 11 | $37,781 | $3,435 |
| Rifampin | 41 | $2,627 | $64 |
| Ethambutol | 24 | $1,795 | $75 |
See all 11 drugs
| Genvoya | 28 | $140,305 | $5,011 |
| Biktarvy | 25 | $106,819 | $4,273 |
| Odefsey | 11 | $37,781 | $3,435 |
| Rifampin | 41 | $2,627 | $64 |
| Ethambutol | 24 | $1,795 | $75 |
| Azithromycin | 19 | $693 | $36 |
| Amoxicillin | 23 | $416 | $18 |
| Cephalexin | 18 | $384 | $21 |
| Ceftriaxone | 13 | $313 | $24 |
| Penicillin V | 21 | $231 | $11 |
| Isoniazid | 12 | $82 | $7 |
Year by year
| 2024 | 396 | 80 | 0% (0) | 24% | $471,882 |
| 2023 | 380 | 75 | 0% (0) | 8% | $260,082 |
| 2022 | 411 | 68 | 0% (0) | None | $126,812 |
| 2021 | 604 | 86 | 0% (0) | 7% | $126,327 |
| 2020 | 224 | 45 | 0% (0) | 6% | $60,220 |
| 2019 | 253 | 56 | 0% (0) | 10% | $69,528 |
| 2018 | 247 | 52 | None | 8% | $34,971 |
| 2017 | 231 | 61 | 0% (0) | 13% | $26,523 |
| 2016 | 314 | 12 | 0% (0) | 47% | $162,902 |
| 2015 | 275 | 17 | 0% (0) | 63% | $177,094 |
| 2014 | 167 | 28 | 0% (0) | None | $42,727 |
| 2013 | 111 | 17 | None | 11% | $12,253 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Rifampin | 49 | $3,773 | $77 |
| Ampicillin | 21 | $3,552 | $169 |
| Ethambutol | 19 | $1,863 | $98 |
| Azithromycin | 28 | $1,514 | $54 |
| Vancomycin | 13 | $1,500 | $115 |
| Ceftriaxone | 26 | $762 | $29 |
| Amoxicillin | 32 | $442 | $14 |
| Cephalexin | 19 | $284 | $15 |
| Isoniazid | 32 | $236 | $7 |
2022: 11 drugs
| Rifampin | 43 | $3,175 | $74 |
| Ampicillin | 30 | $3,151 | $105 |
| Ethambutol | 32 | $2,635 | $82 |
| Azithromycin | 40 | $1,538 | $38 |
| Ceftriaxone | 34 | $1,208 | $36 |
| Clindamycin | 12 | $640 | $53 |
| Amoxicillin | 22 | $381 | $17 |
| Pantoprazole | 25 | $356 | $14 |
| Penicillin V | 13 | $179 | $14 |
| Isoniazid | 13 | $144 | $11 |
| Mupirocin | 11 | $95 | $9 |
2021: 18 drugs
| Oxacillin | 19 | $13,561 | $714 |
| Cefepime | 29 | $10,279 | $354 |
| Ceftriaxone | 48 | $7,932 | $165 |
| Pyrazinamide | 22 | $5,326 | $242 |
| Rifampin | 81 | $5,270 | $65 |
| Meropenem | 16 | $5,181 | $324 |
| Ampicillin | 20 | $3,526 | $176 |
| Ethambutol | 45 | $3,351 | $74 |
| Vancomycin | 14 | $2,823 | $202 |
| Azithromycin | 36 | $1,559 | $43 |
| Fluconazole | 16 | $1,130 | $71 |
| Cefazolin | 20 | $1,109 | $55 |
| Pantoprazole | 24 | $417 | $17 |
| Ciprofloxacin | 14 | $354 | $25 |
| Isoniazid | 32 | $258 | $8 |
| Sulfamethoxazole-Trimethoprim | 11 | $210 | $19 |
| Penicillin V | 14 | $203 | $15 |
| Mupirocin | 14 | $151 | $11 |
2020: 8 drugs
| Meropenem | 17 | $4,237 | $249 |
| Vancomycin | 21 | $3,746 | $178 |
| Rifampin | 13 | $914 | $70 |
| Ethambutol | 18 | $792 | $44 |
| Ceftriaxone | 16 | $548 | $34 |
| Sulfamethoxazole-Trimethoprim | 12 | $235 | $20 |
| Penicillin V | 12 | $161 | $13 |
| Mupirocin | 11 | $104 | $9 |
2019: 6 drugs
| Rifampin | 24 | $1,704 | $71 |
| Azithromycin | 18 | $1,289 | $72 |
| Ethambutol | 30 | $1,233 | $41 |
| Ceftriaxone | 21 | $1,120 | $53 |
| Penicillin V | 13 | $295 | $23 |
| Isoniazid | 13 | $80 | $6 |
2018: 7 drugs
| Pyrazinamide | 14 | $3,179 | $227 |
| Ethambutol | 31 | $2,554 | $82 |
| Rifampin | 29 | $2,204 | $76 |
| Ampicillin | 11 | $1,565 | $142 |
| Ceftriaxone | 17 | $1,529 | $90 |
| Penicillin V | 15 | $366 | $24 |
| Isoniazid | 24 | $200 | $8 |
2017: 8 drugs
| Vancomycin | 12 | $4,062 | $339 |
| Rifampin | 35 | $2,676 | $76 |
| Ethambutol | 11 | $995 | $90 |
| Azithromycin | 12 | $562 | $47 |
| Ceftriaxone | 11 | $462 | $42 |
| Sodium Chloride | 14 | $265 | $19 |
| Isoniazid | 32 | $194 | $6 |
| Ciprofloxacin | 12 | $133 | $11 |
2016: 13 drugs
| Truvada | 30 | $44,624 | $1,487 |
| Atripla | 11 | $26,615 | $2,420 |
| Reyataz | 13 | $18,039 | $1,388 |
| Intelence | 12 | $13,244 | $1,104 |
| Viread | 12 | $11,988 | $999 |
| Epivir | 12 | $5,003 | $417 |
| Norvir | 13 | $3,404 | $262 |
| Omega-3 Acid Ethyl Esters | 13 | $2,452 | $189 |
| Pravastatin | 20 | $302 | $15 |
| Tamsulosin | 12 | $236 | $20 |
| Sucralfate | 11 | $221 | $20 |
| Hydrochlorothiazide | 22 | $111 | $5 |
| Metformin | 22 | $91 | $4 |
2015: 11 drugs
| Truvada | 38 | $53,552 | $1,409 |
| Atripla | 11 | $28,607 | $2,601 |
| Reyataz | 17 | $22,110 | $1,301 |
| Intelence | 13 | $14,448 | $1,111 |
| Viread | 14 | $13,333 | $952 |
| Norvir | 19 | $5,736 | $302 |
| Epivir | 13 | $5,561 | $428 |
| Pravastatin | 11 | $277 | $25 |
| Sucralfate | 11 | $250 | $23 |
| Hydrochlorothiazide | 23 | $121 | $5 |
| Benazepril | 11 | $47 | $4 |
2014: 3 drugs
| Simvastatin | 15 | $160 | $11 |
| Benazepril | 11 | $127 | $12 |
| Lisinopril | 11 | $72 | $7 |
Money from drug and device companies
$69 in 2025
| 2025 | 2 | 3 | None | $69 |
| 2020 | 1 | 1 | None | $16 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | Biktarvy | $42 | 2 payments
|
| Paratek Pharmaceuticals | Nuzyra | $27 | 1 payment
|
See all 3 published payments
| Gilead Sciences | Meals · 2025-11-24 | Biktarvy | $23 |
| Gilead Sciences | Meals · 2025-10-02 | Biktarvy | $19 |
| Paratek Pharmaceuticals | Meals · 2025-09-29 | Nuzyra | $27 |
See earlier years (2020)
2020: $16
| Insmed | None | $16 | 1 payment
|
Professional record
- NPI
- 1174847933
- Licence
- CA A121423California A121423: Current · expires 2028-02-29
- Trained
- Loma Linda University School of Medicine, 2010
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X); Student in a training program (390200000X)
- Mailing address
- 2350 W. El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2010-03-23
- NPI last updated
- 2016-10-07
This is when the NPI record was last certified, not a medical board exam.